121 related articles for article (PubMed ID: 3058970)
1. In vivo demonstration of microvascular pathology by intravital microscopy in experimental chronic graft-versus-host disease: analogy with scleroderma.
Bos G; Majoor G; Slaaf D; Reneman R; van Breda Vriesman P
J Rheumatol; 1988 Sep; 15(9):1339-45. PubMed ID: 3058970
[TBL] [Abstract][Full Text] [Related]
2. Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models.
Bos GM; Majoor GD; Slaaf DW; van de Gaar MJ; Weijmer-van Velzen JS; van Breda Vriesman PJ
Transplant Proc; 1989 Apr; 21(2):3262-3. PubMed ID: 2652812
[No Abstract] [Full Text] [Related]
3. Is graft-versus-host disease a reliable model for scleroderma?
Mekori YA; Claman HN
Ric Clin Lab; 1986; 16(4):509-13. PubMed ID: 3576048
[TBL] [Abstract][Full Text] [Related]
4. Bullous sclerodermalike changes in chronic graft-vs-host disease.
Hymes SR; Farmer ER; Burns WH; Morison WL; Tutschka PJ; Walters LL; Santos GW
Arch Dermatol; 1985 Sep; 121(9):1189-92. PubMed ID: 3899019
[TBL] [Abstract][Full Text] [Related]
5. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
McCormick LL; Zhang Y; Tootell E; Gilliam AC
J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
[TBL] [Abstract][Full Text] [Related]
6. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.
Bell SA; Faust H; Mittermüller J; Kolb HJ; Meurer M
Br J Dermatol; 1996 May; 134(5):848-54. PubMed ID: 8736324
[TBL] [Abstract][Full Text] [Related]
7. Scleroderma-like changes in chronic graft vs host disease.
Spielvogel RL; Goltz RW; Kersey JH
Arch Dermatol; 1977 Oct; 113(10):1424-8. PubMed ID: 20854
[TBL] [Abstract][Full Text] [Related]
8. Animal models of scleroderma.
Lakos G; Takagawa S; Varga J
Methods Mol Med; 2004; 102():377-93. PubMed ID: 15286396
[TBL] [Abstract][Full Text] [Related]
9. Murine models of graft-versus-host disease with features of scleroderma.
Charley MR; Deng JS
Immunol Ser; 1989; 46():625-40. PubMed ID: 2488872
[No Abstract] [Full Text] [Related]
10. Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantation.
Haeusermann P; Kump E; Rovó A; Tichelli A; Itin P; Gratwohl A; Biedermann BC
Dermatology; 2009; 219(1):32-41. PubMed ID: 19407437
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
Bhattacharyya S; Ghosh AK; Pannu J; Mori Y; Takagawa S; Chen G; Trojanowska M; Gilliam AC; Varga J
Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
[TBL] [Abstract][Full Text] [Related]
12. Composite vascularized skin/bone transplantation models for bone marrow-based tolerance studies.
Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Siemionow M
Ann Plast Surg; 2006 Mar; 56(3):295-300. PubMed ID: 16508361
[TBL] [Abstract][Full Text] [Related]
13. Mast cells in murine graft-versus-host disease: a model of immunologically induced fibrosis.
Choi KL; Claman HN
Immunol Ser; 1989; 46():641-51. PubMed ID: 2488873
[No Abstract] [Full Text] [Related]
14. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
[TBL] [Abstract][Full Text] [Related]
15. Case report: progressive systemic sclerosis-like syndrome after bone marrow transplantation. Clinical, immunologic, and pathologic findings.
Herzog P; Clements PJ; Roberts NK; Furst DE; Johnson CE; Feig SA
J Rheumatol; 1980; 7(1):56-64. PubMed ID: 6986468
[TBL] [Abstract][Full Text] [Related]
16. [Chronic graft-versus-host reaction following bone marrow transplantation].
Ippen H; Nagel G
Hautarzt; 1984 Apr; 35(4):182-7. PubMed ID: 6373672
[TBL] [Abstract][Full Text] [Related]
17. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
Voltarelli JC; Ahmed H; Paton EJ; Stracieri AB; Holman P; Bashey A; Coutinho M; Simoes BP; Ball ED; Carrier E
Bone Marrow Transplant; 2001 Jul; 28(1):97-9. PubMed ID: 11498752
[TBL] [Abstract][Full Text] [Related]
19. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
[TBL] [Abstract][Full Text] [Related]
20. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man.
Janin-Mercier A; Devergie A; Van Cauwenberge D; Saurat JH; Bourges M; Lapiere CM; Gluckman E
Am J Pathol; 1984 May; 115(2):296-306. PubMed ID: 6372497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
